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Purpose: We examined risk of myocardial infarction and all-cause death associated with the
extent of coronary artery disease ascertained by coronary angiography in patients with
diabetes mellitus. We hypothesized that risks of myocardial infarction and death were
associated with extent of coronary artery disease in diabetes patients.
Patients and methods: Weconducted a cohort study of patientswith type 1 and type 2 diabetes,
who underwent coronary angiography from 2004 to 2012. Patients were stratified according to
extent of coronary artery disease: 0-, 1-, 2- or 3-vessel disease or diffuse vessel disease. Endpoints
were myocardial infarction, all-cause death, and major adverse cardiovascular events (MACE),
defined as the composite of myocardial infarction, cardiac death, or ischemic stroke. Adjusted
incidence and mortality rate ratios (IRRsadj) were calculated using patients with 0-vessel disease as
the reference group. Median follow-up was 3 years for a total of 45,164 person-years.
Results: The study included 12,594 diabetes patients. Of these, 3,147 (25.0%) had 0-vessel
disease, 1,195 (9.5%) had diffuse vessel disease, 3,001 (23.8%) had 1-vessel disease, 2,220
(17.6%) had 2-vessel disease, and 3,031 (24.1%) had 3-vessel disease. The myocardial infarction
rate was 0.4 per 100 person-years (95% CI: 0.3–0.5) in patients with 0-vessel disease. Using
patients with 0-vessel disease as reference, the risk of myocardial infarction increased according
to the number of diseased vessels (diffuse vessel disease: 1.4 per 100 person-years, IRRadj 3.87,
95% CI: 2.41–6.23; 1-vessel disease: 1.9 per 100 person-years, IRRadj 4.99, 95% CI: 3.33–7.46;
2-vessel disease: 2.7 per 100 person-years, IRRadj 7.14, 95% CI: 4.78–10.65; and 3-vessel
disease: 4.3 per 100 person-years, IRRadj 11.42, 95% CI: 7.76–16.82; ptrend<0.001). Similar
associations were observed for all-cause death and MACE.
Conclusion: The extent of coronary artery disease is a major risk factor for myocardial
infarction and death in patients with diabetes mellitus.
Keywords: coronary angiography, epidemiology, Western Denmark Heart Registry, death
Introduction
Only a few studies with either short-term follow-up after coronary angiography
(CAG) or long-term follow-up after coronary computed tomography have examined
the association between extent of coronary artery disease (CAD) and clinical out-
comes in patients with diabetes mellitus.1–3 We hypothesized that the risk of
myocardial infarction (MI) and death is associated with the extent of CAD in
diabetes patients. If so, a differentiated characterization of the extent of CAD
may have a perspective for more individualized preventive treatment strategies
for diabetes patients than currently used.
Correspondence: Michael Maeng
Department of Cardiology, Palle Juul-
Jensens Boulevard 99, Aarhus N 8200,
Denmark
Tel +459 936 4429
Fax +457 845 2117
Email michael.maeng@clin.au.dk
Clinical Epidemiology Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com Clinical Epidemiology 2019:11 419–428 419
DovePress © 2019 Gyldenkerne et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/
terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing
the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
http://doi.org/10.2147/CLEP.S200173
Assessment of CAD by CAG has been described as a
valid prognostic tool in risk stratification of diabetes
patients.4 In the current study, we conducted a median
follow-up of 3 years in diabetes patients undergoing
CAG to evaluate whether increasing extent of obstructive
CAD is associated with incremental MI and death rates.
Material and methods
Data sources
Each Danish resident is assigned a unique and permanent 10-
digit personal identifier at birth or upon immigration. This
identifier is included in every Danish health registry and
enables accurate long-term follow-up data with minimal
risk of loss to follow-up. The Western Denmark Heart
Registry (WDHR) is a clinical database containing informa-
tion on all patients referred for diagnostic, invasive, and
surgical procedures since 1999 inWestern Denmark (popula-
tion: 3.3 million people).5,6 TheWDHR has collected data on
>240,000 CAGs, including a detailed description of the pre-
sence and extent of CAD. In addition to the WDHR, we used
the following databases in the current study: the Civil
Registration System, which collects data on all Danish resi-
dents’ vital status (dead, alive, or emigrated); the Danish
National Patient Registry, which includes all inpatient and
outpatient hospital diagnoses in Denmark; and the Danish
National Health Service Prescription Database, which regis-
ters data on all reimbursed prescriptions redeemed at Danish
pharmacies.7–9 According to Danish law, observational reg-
istry-based studies require no approval from local or national
ethics committees.
Diabetes
Diabetes patients, with type 1 or type 2 diabetes patients,
were identified through the WDHR and the Danish
National Health Service Prescription Database.5,6,9 In the
WDHR, diabetes patients are classified according to their
diabetes treatment (insulin ± oral glucose-lowering treat-
ment, oral glucose-lowering treatment, or nonpharmacolo-
gical dietary treatment) at the time of CAG intervention.
To confirm this information and to include newly diag-
nosed diabetes patients, we also used the Danish National
Health Service Prescription Database to identify patients
who had redeemed of ≥1 prescription for anti-diabetes
treatment (insulin or non-insulin diabetes medication)
within 6 months before and 1 month after CAG.
Relevant Anatomical Therapeutic Chemical codes are pro-
vided in the supplementary material, Table S1.
Coronary artery disease
Patients were stratified according to extent of CAD, ie the
number of coronary arteries with obstructive CAD (defined
as ≥50% angiographic stenosis): 0-, 1-, 2- or 3-vessel dis-
ease (VD), or diffuse VD (ie nonobstructive CAD, defined
as <50% stenosis in >1 coronary vessel).
Patient selection
All diabetes patients with a CAG procedure registered in
the WDHR from July 1, 2004 to July 30, 2012 were
included in the study (Figure 1). Patients without dia-
betes were excluded (N=82,980). For patients who
underwent multiple CAG examinations during the
study period the first CAG was regarded as the index
procedure. Patients classified as having no CAD despite
previous MI, percutaneous coronary intervention, and/or
coronary artery bypass grafting were excluded due to
risk of misclassification (N=396). Patients who died or
emigrated <30 days after CAG (N=416) also were
excluded. All patients were ≥18 years old.
Comorbidity
Comorbidities were evaluated using the Charlson
Comorbidity Index score based on ICD-10 codes (supple-
mentary material, Table S2) registered in the Danish
National Patient Registry. We used a 5-year look-back
period of patient history before the study inclusion date.10
A modified Charlson Comorbidity Index score (excluding
“diabetes” and “diabetes with end-organ damage”) was
estimated for each patient on the date of the index CAG.
Medication
Records of treatment with statins, aspirin, adenosine dipho-
sphate (ADP) receptor inhibitors, angiotensin-converting-
enzyme (ACE) inhibitors/angiotensin II receptor blockers,
β-blockers, and calcium channel blockers were ascertained
from the Danish National Health Service Prescription
Database (anatomical therapeutic chemical codes are provided
in the supplementary material, Table S1).9 Treatment was
defined as reimbursement for a redeemed prescription between
6 months before and 1 month after the index CAG date.
Myocardial infarction
MI diagnoses were obtained from the Danish National
Patient Registry (Supplementary Material, Table S2).
Follow-up began 30 days after CAG, as an MI diagnosis
has shown less validity during the first 30 days after CAG
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(due to interhospital patient transfers and initial double
registration of MI).11
All-cause death
Information on all-cause death was obtained from the Civil
Registration System. The Civil Registration System is
virtually complete, with approximately 0.3% persons lost
to follow-up.12
Major adverse cardiovascular events
Major adverse cardiovascular events (MACE) were defined as
the composite of MI, ischemic stroke, and cardiac death.
Ischemic stroke was ascertained from the Danish National
Patient Registry (ICD-10 codes: DI-63-64). Cardiac death
was obtained from death certificates (ICD-10 codes: DI-20-
25, DI-46, DI-47.2, DI-50, R-96) from the Danish Register of
Causes of Death.13
Statistical analyses
Follow-up began 30 days after the index CAG. For MI,
follow-up continued until first MI, death, emigration, or end
of follow-up (December 31, 2012), whichever occurred first.
For death, follow-up continued until death, emigration, or end
of follow-up. For MACE, follow-up continued until MI,
ischemic stroke, death, emigration, or end of follow-up. Due
to lack of access to death certificates in 2012, patient inclusion
was restricted to June 30, 2011 and end of follow-up was
December 31, 2011 for MACE. We estimated event rates for
MI, death, and MACE per 100 person-years and constructed
cumulative incidence proportion curves corresponding to the
seventy-fifth percentile of follow-up. As the data did not meet
criteria for proportional hazards, we subsequently estimated
incidence rate ratios (IRRs) and adjusted IRRs (IRRsadj) for
the clinical endpoints using modified Poisson regression with
the event as the outcome and the natural log of person-years as
the offset.14 Patients with 0-VD were used as reference. IRRs
were adjusted for age, sex, smoking status, hypertension,
modified Charlson Comorbidity Index score, and also for
treatment with aspirin, statins, ADP receptor inhibitors,
β-blockers, ACE inhibitors, angiotensin II receptor blockers,
and calcium channel blockers. Since wewere using amodified
Poisson regression, adjusting for death as a competing risk was
not relevant. We conducted a log-rank test for trend for each
endpoint, stratified by CAD extent. We performed complete
case analyses in the multivariable regression analyses. In these
analyses, we only had missing values for smoking (11%). We
also conducted a subgroup analysis for elective patients
(N=7,664). Statistical analyses were conducted using Stata/
IC software version 13.1 (Statacorp LP, College Station,
Texas, USA).
91,583 patients undergoing CAG
78,175 patients without diabetes
2 patients <18 years old
396 patients with no CAD and
previous MI, PCI, and/or CABG
416 patients who died or emigrated
<30 days after CAG
12,594 diabetes patients
3,147 patients
with 0-VD
1,195 patients
with diffuse VD
3,001 patients
with 1-VD
2,220 patients
with 2-VD
3,031 patients
with 3-VD
Figure 1 Flowchart of selection of diabetes patients who underwent coronary angiography in Western Denmark between July 1, 2004 and July 30, 2012.
Abbreviations: CAG, coronary angiography; CAD, coronary artery disease; MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery
bypass graft; VD, vessel disease.
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Results
A total of 12,594 diabetes patients underwent CAG during the
study period. Among these patients, 3,147 (25.0%) had 0-VD,
1,195 (9.5%) had diffuse VD, 3,001 (23.8%) had 1-VD, 2,220
(17.6%) had 2-VD, and 3,031 (24.1%) had 3-VD (Figure 1).
Median follow-up-time was 3.0 years (Q1-Q3: 1.1–5.0 years),
for a total of 45,164 person-years. None were lost to fol-
low-up.
Baseline characteristics
Diabetes patients with obstructive CAD (1-3 VD) were
more often male, older, active smokers, and with reim-
bursed prescriptions for aspirin, statins, β-blockers, cal-
cium channel blockers, ACE-inhibitors, and ADP
receptor inhibitors than patients without obstructive CAD
(Table 1). Furthermore, patients with obstructive CAD
were more likely to undergo acute or subacute CAG.
Clinical endpoints
During the follow-up period, 949 patients had an MI and
2,443 patients died. Numbers of events stratified by extent
of CAD are summarized in Table 2. Cumulative 5-year
incidence proportion curves for MI, death, and MACE are
displayed in Figure 2.
We observed an incremental increase in the MI event
rate per 100 person-years by extent of CAD (Table 2).
Patients with 0-VD (0.4 MI per 100 person-years) had the
lowest risk and patients with 3-VD (4.3 MI per 100 per-
son-years) had the highest risk. Using patients with 0-VD
as reference, the risk of MI increased by number of dis-
eased vessels (Table 2; ptrend<0.001).
For all-cause death, event rates also increased according to
the number of diseased vessels (Table 2). Patients with 0-VD
had the lowest risk (3.1 deaths per 100 person-years) and
patients with 3-VD the highest risk (8.1 deaths per 100 per-
son-years). Using patients with 0-VD as reference, the risk of
death increased by number of diseased vessels (Table 2;
ptrend<0.001).
For MACE, we similarly observed increasing event rates
by extent of CAD (Table 2). Patients with 0-VD had the lowest
risk (1.7 deaths per 100 person-years) and patients with 3-VD
the highest risk (8.7 deaths per 100 person-years). Using
patients with 0-VD as reference, the risk of MACE increased
by number of diseased vessels (Table 2; ptrend<0.001).
For both MI, death, and MACE, the curves, and thus the
risk, for different extents of CAD continued to diverge, rather
than stabilize, over at least a 5-year period (Figure 2).
Subgroup analysis of patients undergoing elective CAG,
yielded similar results of both MI and death (Table 3).
Discussion
The present study’s primary finding is that the extent of
CAD ascertained by CAG in diabetes patients was asso-
ciated with an increased rate of MI, all-cause death, and
MACE in our cohort with a median of 3.0 years and a
seventy-fifth percentile of 5.0 years follow-up.
The current study expands a previous report based on
the same patient cohort.4 The earlier report showed that (i)
diabetes patients without CAD have a similar risk of MI as
non-diabetes patients without CAD, and (ii) diabetes
patients with CAD have a higher risk of MI than non-
diabetes patients with CAD. In the current analysis, we
extend these results by showing that it is not only the
presence but also the extent of CAD that defines the risk
of MI and death among diabetes patients. Furthermore, we
show that the differences in risk continue to increase,
rather than stabilize, over at least a 5-year period. It is
important to note that our study included diabetes patients
undergoing CAG for a clinical indication. Therefore, our
conclusions are not necessarily applicable for asympto-
matic patients with diabetes.
A cohort study of US veterans undergoing elective
coronary angiography for CAD, also found that increasing
extent of CAD was associated with a progressively greater
risk of MI and all-cause mortality, both in a mixed cohort
(N=37,674) and in a diabetes subgroup (N=15,699).1 The
study differed from ours in several important aspects.
First, US veterans are not representative of a general
CAG cohort, being 90% male, 39% obese, and 26% hav-
ing posttraumatic stress disorder. At the same time, our
study population does not represent ethnic subgroups,
since the Danish population is primarily Caucasian.
Second, follow-up was limited to 1 year in the US veteran
cohort, compared to a median of 3 years and a seventy-
fifth percentile of 5 years in our study. Third, the US
veterans study included only elective patients, while our
cohort consisted of consecutive patients, among whom a
high proportion had an acute coronary syndrome. Fourth,
it should be noted that the two studies used different
definitions of vascular disease. In the study of US veter-
ans, nonobstructive VD was defined as ≥1 stenosis ≥20%
but <70% and obstructive VD was defined as any stenosis
≥70% or left main stenosis ≥50%.1 Despite these differ-
ences, our study—including our subgroup analysis for
elective patients only—and the US veterans study had
Gyldenkerne et al Dovepress
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consistent results, with both finding an incremental risk of
adverse cardiac events with increasing extent of CAD.
The CONFIRM (Coronary CT Angiography
Evaluation for Clinical Outcomes: An International
Multicenter) registry followed 1,823 diabetes patients
for 5 years, using coronary computed tomography
angiography (CCTA).2 Similar to the current study, mor-
tality increased with the extent of CAD in the
CONFIRM diabetes cohort. However, the CONFIRM
diabetes analysis did not examine MI as an individual
endpoint. Instead, MACE (defined as death, MI,
unstable angina, or late coronary revascularization) was
examined in a subgroup of diabetes patients (N=973)
and showed a similar incremental association between
CAD extent and MACE occurrence. The CONFIRM
diabetes cohort enrolled elective patients, unlike our
study, which enrolled all-comers including a high pro-
portion of patients with acute coronary syndromes.
Table 1 Baseline characteristics of diabetes patients at the time of coronary angiography, Denmark, 2004–2012
0-VD
(N=3,147)
Diffuse VD (N=1,195) 1-VD
(N=3,001)
2-VD
(N=2,220)
3-VD
(N=3,031)
Total
(N=12,594)
Follow-up, years 3.0 (1.1–5.0) 2.1 (1.0–4.0) 3.0 (1.1–5.1) 3.0 (1.1–5.1) 3.0 (1.1–4.0) 3.0 (1.1–5.0)
Age, years 61 (53–69) 65 (59–73) 65 (59–73) 67 (61–75) 68 (62–75) 65 (59–73)
Male sex, % 51.0 64.1 68.1 72.1 75.1 66.0
Current smoking, % 23.0 24.1 30.0 28.0 25.1 26.1
Hypertension, % 79.0 86.0 80.0 81.1 83.1 81.1
MI <30 days after CAG, % 1.1 3.0 23.0 20.1 18.1 14.0
Medical treatment
Aspirin, % 65.0 76.0 83.1 85.1 87.1 79.1
Statins, % 73.1 85.0 88.0 89.1 89.0 84.1
ADP-inhibitors, % 4.0 7.1 44.1 41.1 31.1 27.0
blockers, % 56.1 64.0 74.1 78.1 80.0 71.0
ACE-inhibitors, % 47.1 53.0 54.1 57.1 60.0 54.1
Calcium channel blockers, % 35.1 42.1 37.0 42.0 46.0 40.0
ARBs, % 30.0 34.0 28.1 26.1 28.0 29.0
Modified Charlson Comorbidity Index score
0, % 59.0 51.0 58.1 54.1 51.1 55.1
1, % 24.1 25.1 22.0 24.1 26.1 24.1
2, % 10.1 14.1 11.1 12.1 13.0 12.0
≥3, % 5.1 8.0 7.1 7.0 8.1 7.0
Procedural indication
STEMI, % 2.1 1.0 17.1 14.1 11.0 10.0
NSTEMI, % 7.0 10.1 19.0 24.0 28.1 18.1
Unstable AP, % 2.0 2.0 1.1 2.0 1.0 1.1
Stable AP, % 50.1 55.1 42.1 44.0 43.0 46.0
Arrhythmia, % 2.1 2.0 2.0 1.1 2.0 2.0
Valve disease, % 9.1 7.1 7.0 5.1 3.1 6.1
Cardiomyopathy, % 9.1 7.1 4.1 4.0 6.1 6.1
Unspecified chest pain, % 5.1 5.1 1.1 0.1 0.1 2.1
Other, % 9.0 6.1 3.1 3.0 2.0 4.1
Procedural priority
Acute/subacute, % 23.0 24.0 45.1 47.1 48.1 39.0
Elective, % 76.1 75.1 54.0 52.0 51.0 60.1
Notes: Data are presented as median (Q1–Q3), mean (Q1–Q3), or %.
Abbreviations: VD, vessel disease; MI, myocardial infarction; CAG, coronary angiography; ADP, adenosine diphosphate; ACE, angiotensin-converting enzyme; ARB,
angiotensin-II receptor blocker; STEMI, ST-elevation myocardial infarction; NSTEMI, non-ST-elevation myocardial infarction; AP, angina pectoris.
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Out study extends previous 1-year CAG data out to 5
years and also represents consecutively enrolled patients,
many exhibiting acute coronary syndromes, rather than
elective patients. Further, we find comparable results in
comparison to an elective CCTA cohort. The fact that
these studies, despite being performed in different coun-
tries, in elective and all-comer cohorts, and using different
imaging modalities, strengthen the conclusions and the
external validity.
The CAG and CCTA studies described above provide a
rationale for performing prospective randomized studies to test
individualized primary prophylactic strategies. Only a single
randomized clinical trial has examined targeted patient care
guided by CCTA vs optimal patient care in asymptomatic
diabetes patients.15 The trial did not find screening of CAD
beneficial as screening did not reduce the composite rate of all-
cause mortality, nonfatal MI, or unstable angina requiring
hospitalization at 4 years. However, the trial predominantly
included low-risk diabetes patients with normal or nonobstruc-
tive CAD, which nearly eliminated the probability of detecting
differences in outcomes. Rather than randomizing asympto-
matic patients to CCTA or not, we suggest that CCTA should
be used for risk stratification before randomization. Based on
the current results, it seems likely that asymptomatic patients
with diabetes and obstructive 2-VD and 3-VD will benefit
from intensive prophylactic medical treatments, eg with
novel strategies such as sodium-glucose cotransporter-2
(SGLT-2) inhibitors,16 glucagon-like peptide-1 (GLP-1)
analogues,17,18 PCSK9 inhibitors,19 and the monoclonal anti-
body canakinumab targeting interleukin-1β.20 However, this
has to be tested in prospective randomized clinical trials.
The ASCEND (A Study of Cardiovascular Events in
Diabetes) study21 recently examined whether aspirin should
be used as primary prophylactic treatment in diabetes
patients. It showed that the benefits of aspirin with preven-
tion of serious vascular events (12% reduced relative risk)
were largely counterbalanced by a high occurrence of major
bleeding events (29% higher relative risk), when used for
primary prevention in diabetes patients. This questions the
use of aspirin as primary prophylaxis in patients with
asymptomatic CAD.21 In our study, diabetes patients with
0-VD exhibited a low cardiovascular risk and it may be
considered to discontinue treatment with aspirin in these
patients. As our results confirm, the 0-VD patients have a
very low risk of MI, so they will only have the risk of
bleeding complications with aspirin treatment.
Table 2 Number of events and rates of myocardial infarction, death and major adverse cardiovascular events in patients with diabetes,
by extent of coronary artery disease
Events
(N)
Rate per 100 person-years
(95%CI)
Unadjusted IRR
(95%CI)
Adjusted IRRa
(95%CI)
Myocardial infarction
0-VD 41 0.4 (0.3–0.5) 1 1
Diffuse VD 46 1.4 (1.0–1.8) 3.80 (2.50–5.79) 3.87 (2.41–6.23)
1-VD 203 1.9 (1.7–2.2) 5.36 (3.83–7.49) 4.99 (3.33–7.46)
2-VD 213 2.7 (2.4–3.1) 7.56 (5.41–10.57) 7.14 (4.78–10.65)
3-VD 446 4.3 (4.0–4.8) 12.07 (8.76–16.63) 11.42 (7.76–16.82)
All-cause death
0-VD 359 3.1 (2.8–3.5) 1 1
Diffuse VD 172 5.0 (4.3–5.8) 1.61 (1.34–1.93) 1.35 (1.11–1.66)
1-VD 507 4.6 (4.3–5.1) 1.48 (1.29–1.70) 1.31 (1.12–1.54)
2-VD 506 6.1 (5.6–6.7) 1.96 (1.71–2.25) 1.69 (1.45–1.98)
3-VD 899 8.1 (7.6–8.6) 2.58 (2.29–2.92) 2.01 (1.73–2.33)
MACE
0-VD 141 1.7 (1.4–2.0) 1 1
Diffuse VD 79 3.5 (2.8–4.3) 2.06 (1.56–2.71) 1.62 (1.20–2.17)
1-VD 316 4.0 (3.6–4.4) 2.37 (1.94–2.90) 1.98 (1.58–2.47)
2-VD 344 5.7 (5.2–6.4) 3.43 (2.81–4.18) 2.87 (2.31–3.58)
3-VD 697 8.7 (8.1–9.4) 5.21 (4.34–6.25) 3.96 (3.21–4.87)
Notes: aAdjusted for age, sex, modified Charlson Comorbidity Index score, hypertension, smoking status, and for treatment with aspirin, statins, adenosine diphosphate
receptor inhibitors, β-blockers, ACE-inhibitors, angiotensin-II receptor blockers, and calcium channel blockers, using patients with 0-VD as reference.
Abbreviations: VD, vessel disease; IRR; incidence rate ratio; MACE, major adverse cardiovascular events.
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C
Figure 2 Cumulative incidences of myocardial infarction (A), all-cause death (B), and MACE (C) in diabetes patients with 0-vessel disease, diffuse VD, 1-VD, 2-VD, and 3-
VD. The follow-up period represents the seventy-fifth percentile.
Abbreviations: VD, vessel disease; MACE, major adverse cardiovascular events.
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As our study relied on registry data, we cannot exclude
the possibility of the impact of unmeasured confounding.
Another limitation is that we could not differentiate
between type of diabetes. As well, we could not establish
the duration of diabetes, which is associated with higher
extent of CAD and higher risk of major adverse cardio-
vascular and cerebrovascular events.22–24 The inclusion
period lasted from 2004 to 2012. In this period, acute
care of acute coronary syndromes was substantially
improved by pre-hospital triage based on in-ambulance
ECG leading to bypassing of referral hospitals and direct
transfer to tertiary hospitals with invasive facilities, and by
the introduction of drug-eluting stents. CAG has some
important limitations to address. First, CAG does not
describe lesion morphology and plaque vulnerability in
the vessel wall. Second, it is an invasive procedure,
which limits its use as a screening modality. Third, as
classification of CAD is based on visual angiographic
assessment by the treating physician during CAG, we
cannot exclude a minor degree of interobserver variation.
Fourth, we stratified CAD according to the number of
coronary arteries with obstructive CAD. This is a simpli-
fication of a spectrum of CAD and the results must be
interpreted in this context. With the current classification
we were nevertheless able to identify diabetes patients at
low, intermediate, and high risk. We were unable to further
stratify patients according to the number of coronary seg-
ments/arteries with nonobstructive CAD since only signif-
icant lesions are registered in the WDHR. Moreover, we
cannot determine which patients received revasculariza-
tion therapy, which can affect their prognosis. Finally,
our study was limited to a seventy-fifth percentile of 5.0
years follow-up and interpretation of our data should be
restricted to this period.
Conclusion
Increasing extent of obstructive CAD in diabetes patients
was associated with an incremental rate of MI, death, and
MACE for at least 5 years. Thus, assessment of CAD
extent can assist in identifying diabetes patients at high
risk of cardiovascular events, who may benefit the most
from primary prophylactic measures.
Data availability
According to the Danish law on personal data, we are not
allowed to make the dataset publicly available.
Table 3 Number of events and rates of myocardial infarction and death in elective patients with diabetes, by extent of coronary artery
disease
Events
(N)
Rate per 100 person-years
(95%CI)
Unadjusted IRR
(95%CI)
Adjusted IRRa
(95%CI)
Myocardial infarction
0-VD 27 0.3 (0.2–0.5) 1 1
Diffuse VD 22 0.9 (0.6–1.3) 2.79 (1.59–4.89) 2.58 (1.41–4.73)
1-VD 79 1.4 (1.1–1.7) 4.56 (2.95–7.06) 4.11 (2.51–6.72)
2-VD 87 2.1 (1.7–2.5) 6.72 (4.37–10.35) 6.53 (4.04–10.56)
3-VD 185 3.3 (2.9–3.8) 10.77 (7.19–16.12) 10.04 (6.35–15.88)
All-cause death
0-VD 250 2.8 (2.5–3.2) 1 1
Diffuse VD 99 3.8 (3.1–4.6) 1.35 (1.07–1.70) 1.20 (0.94–1.55)
1-VD 248 4.3 (3.8–4.8) 1.51 (1.27–1.80) 1.32 (1.08–1.62)
2-VD 216 4.9 (4.3–5.6) 1.74 (1.45–2.08) 1.56 (1.27–1.92)
3-VD 379 6.4 (5.8–7.1) 2.26 (1.93–2.65) 1.87 (1.54–2.27)
MACE
0-VD 97 1.5 (1.2–1.8) 1 1
Diffuse VD 44 2.5 (1.8–3.3) 1.72 (1.20–2.46) 1.44 (1.00–2.08)
1-VD 144 3.3 (2.8–3.9) 2.29 (1.77–2.97) 1.88 (1.41–2.52)
2-VD 150 4.5 (3.9–5.4) 3.18 (2.46–4.11) 2.74 (2.07–3.64)
3-VD 298 6.7 (6.0–7.5) 4.64 (3.68–5.85) 3.69 (2.83–4.80)
Notes: aAdjusted for age, sex, modified Charlson Comorbidity Index score, hypertension, smoking status, and for treatment with aspirin, statins, adenosine diphosphate
receptor inhibitors, β-blockers, ACE-inhibitors, angiotensin-II receptor blockers, and calcium channel blockers, using patients with 0-VD as reference.
Abbreviations: VD, vessel disease; IRR, incidence rate ratio; MACE, major adverse cardiovascular events.
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Table S1 Anatomical therapeutic chemical codes used in the Danish National Health Service prescription database
Medication Anatomical therapeutic chemical (ATC) code
Insulin A10A
Non-insulin diabetes medication A10B
Statins C10AA
Aspirin B01AC22, N02BA01
Adenosine diphosphate receptor inhibitors B01AC04, B01AC22, B01AC24
Angiotensin-converting enzyme inhibitors C09A, C09B
Angiotensin II receptor blockers C09C, C09D
Beta-blockers C07
Calcium channel blockers C08C, C08D
Table S2 ICD-10 codes used in the Charlson Comorbidity Index (CCI) score based on data in the Danish National Patient Registry,
including weights of each item included in the CCI
Disease Weight ICD-10 codes
Myocardial infarctiona 1 I21, I22, I23
Congestive heart failure 1 I50, I11.0, I13.0, I13.2
Peripheral vascular disease 1 I70-I74, I77
Cerebrovascular disease 1 I60-I69, G45, G46
Dementia 1 F00-F03, F05.1, G30
Chronic pulmonary disease 1 J40-J47, J60-J67, J68.4, J70.1, J70.3, J84.1, J92.0, J96.1, J98.2, J98.3
Connective tissue disease 1 M05, M06, M08, M09, M30-M36, D86
Ulcer disease 1 K22.1, K25-K28
Mild liver disease 1 B18, K70.0-K70.3, K70.9, K71, K73, K74, K76.0
Diabetes I and II 1 E10.0, E10.1, E10.9, E11.0, E11.1, E11.9
Hemiplegia 2 G81, G82
Moderate to severe kidney disease 2 I12, I13, N00-N05, N07, N11, N14, N17-N19, Q61
Diabetes with end-organ damage 2 E10.2-E10.8, E11.2-E11.8
Any tumor 2 C00-C75
Leukemia 2 C91-C95
Lymphoma 2 C81-C85, C88, C90, C96
Moderate to severe liver disease 3 B15.0, B16.0, B16.2, B19.0, K70.4, K72, K76.6, I85
Metastatic solid tumor 6 C76-C80
AIDS 6 B21-B24
Notes: aICD-10 code I21 was used as a primary or secondary discharge diagnosis during an acute hospitalization for myocardial infarction events 30 days or more after
coronary angiography.
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